Citius Pharma(CTXR) - 2024 Q2 - Quarterly Results

Mino-Lok data analysis on track with topline results anticipated this quarter Exhibit 99.1 Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update LYMPHIR biologics license application accepted with PDUFA target action date set for August 13, 2024 CRANFORD, N.J., May 14, 2024 -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-cl ...